Melane Sampson, Author at BioTuesdays

Feature

Alto disrupting the trial-and-error approach to treating neuropsychiatric disorders

By Melane Sampson Amit Etkin, MD, PhD, founder, president, and CEO of Alto Neuroscience Alto Neuroscience (NYSE: ANRO) is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven...

August 4, 2026

Feature

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

A pharmaceutical and life sciences technology, data, and consulting platform, IntegriChain delivers solutions that help companies manage the commercial and financial complexities of bringing therapies to market...

July 21, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Developments

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

LIR Life Sciences (CSE: SKNY; OTCPK: BBCMF) has announced that it has entered into a services agreement with closely held Oxygen Handel GmbH (OH), a specialized preclinical and regulatory development organization, to...

July 17, 2026

Developments

Dimerix acquires Phase 2-ready asset for acute kidney injury

Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class...

July 17, 2026

Developments

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that...

July 15, 2026

Developments

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Fractyl Health (NASDAQ: GUTS) has announced positive one-year results from its REMAIN-1 Midpoint Cohort reinforcing the potential of the Revita DMR System to be the first durable procedural therapy for post-GLP-1 weight...

July 15, 2026

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Author - Melane Sampson

Alto disrupting the trial-and-error approach to treating neuropsychiatric disorders

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

Dimerix acquires Phase 2-ready asset for acute kidney injury

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Myricx to be acquired by Novartis for $1.5B

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Subscribe